Involvement of cholesterol in the pathogenesis of Alzheimer's disease: Role of statins

Psychiatria Danubina

Volumn 20, Issue 2, 2008, Pages 162-167

  Pregelj, Peter ^a  

^a UNIVERSITY PSYCHIATRIC HOSPITAL   (Slovenia)

Author keywords

Alzheimer's disease; Cholesterol, statins; Sigma receptors; Vascular dementias

Indexed keywords

AMYLOID BETA PROTEIN; CHOLESTEROL; CHOLINESTERASE INHIBITOR; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR;

ALZHEIMER DISEASE; APOPTOSIS; ARTICLE; CEREBROVASCULAR DISEASE; CHOLESTEROL BLOOD LEVEL; COGNITIVE DEFECT; DEGENERATIVE DISEASE; DEMENTIA; HUMAN; PATHOGENESIS; PROTEIN SYNTHESIS; RISK ASSESSMENT;

AGED; ALZHEIMER DISEASE; AMYLOID BETA-PROTEIN; ANIMALS; APOLIPOPROTEINS E; APOPTOSIS; BRAIN; CHO CELLS; CRICETINAE; CRICETULUS; DEMENTIA, VASCULAR; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERCHOLESTEROLEMIA; RECEPTORS, SIGMA; RISK FACTORS;

EID: 47849109721     PISSN: 03535053     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (62)

1. Abad-Rodriguez J, Ledesma MD, Craessaerts K, Perga S, Medina M, Delacourte A, Dingwall C, De Strooper B & Dotti CG: Neuronal membrane cholesterol loss enhances amyloid peptide generation. J Cell Biol 2004; 167:953-60.
2. Alexander CM, Landsman PB, Teutsch SM & Haffner SM: Third National Health and Nutrition Examination Survey; National Cholesterol Education Program. NCEP-defined metabolic syndrome, diabetes, and prevalence of coronary heart disease among NHANES III participants age 50 years and older. Diabetes 2003; 52:1210-4.
3. Arvanitakis Z, Wilson RS, Bienias JL, Evans DA & Bennett DA: Diabetes mellitus and risk of Alzheimer disease and decline in cognitive function. Arch Neurol 2004; 61:661-6.
4. Baskys A & Hou AC: Vascular dementia: pharmacological treatment approaches and perspectives. Clin Interv Aging 2007; 2(3):327-35.
5. Bourrie B, Bribes E, Derocq JM, Vidal H & Casellas P: Sigma receptor ligands: applications in inflammation and oncology. Curr Opin Investig Drugs 2004; 5:1158-63.
6. Buée L, Hof PR, Bouras C, Delacourte A, Perl DP, Morrison JH & Fillit HM: Pathological alterations of the cerebral microvasculature in Alzheimer's disease and related dementing disorders. Acta Neuropathol 1994; 87:469-80.
7. Ciana A, Balduini C & Minetti G: Detergent-resistant membranes in human erythrocytes and their connection to the membrane-skeleton. J Biosci 2005; 30:317-28.
8. Corder EH, Saunders AM, Risch NJ, Strittmatter WJ, Schmechel DE, Gaskell PC Jr, Rimmler JB, Locke PA, Conneally PM & Schmader KE: Protective effect of apolipoprotein E type 2 allele for late onset Alzheimer disease. Nat Genet 1994; 7:180-4.
9. Corder EH, Saunders AM, Strittmatter WJ, Schmechel DE, Gaskell PC, Small GW, Roses AD, Haines JL & Pericak-Vance MA: Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families. Science 1993; 261: 921-3.
10. Dias WB & Hart GW: O-GlcNAc modification in diabetes and Alzheimer's disease. Mol Biosyst. 2007; 3:766-72.
11. Dong LM, Parkin S, Trakhanov SD, Rupp B, Simmons T, Arnold KS, Newhouse YM, Innerarity TL & Weisgraber KH: Novel mechanism for defective receptor binding of apolipoprotein E2 in type III hyperlipoproteinemia. Nat Struct Biol 1996; 3: 718-22.
12. Erkinjuntti T: Cerebrovascular dementia: a guide to diagnosis and treatment. CNS Drugs 1999; 12:35-48.
13. Erkinjunttia T: Cerebrovascular disease, vascular cognitive impairment and dementia. Psychiatry 2008; 7:15-9.
14. Evans RM, Emsley CL, Gao S, Sahota A, Hall KS, Farlow MR & Hendrie H: Serum cholesterol, APOE genotype, and the risk of Alzheimer's disease: a population-based study of African Americans. Neurology 2000; 54:240-2.
15. Evans RM, Hui S, Perkins A, Lahiri DK, Poirier J & Farlow MR: Cholesterol and APOE genotype interact to influence Alzheimer disease progression. Neurology 2004; 62:1869-71.
16. Fassbender K, Simons M, Bergmann C, Stroick M, Lutjohann D, Keller P, Runz H, Kuhl S, Bertsch T, von Bergmann K, Hennerici M, Beyreuther K & Hartmann T: Simvastatin strongly reduces levels of Alzheimer's disease beta -amyloid peptides Abeta 42 and Abeta 40 in vitro and in vivo. Proc Natl Acad Sci U S A 2001; 98:5856-61.
17. Franke C, Nöldner M, Abdel-Kader R, Johnson-Anuna LN, Gibson Wood W, Müller WE & Eckert GP: Bcl-2 upregulation and neuroprotection in guinea pig brain following chronic simvastatin treatment. Neurobiol Dis 2007; 25:438-45.
18. Hall K, Murrell J, Ogunniyi A, Deeg M, Baiyewu O, Gao S, Gureje O, Dickens J, Evans R, Smith-Gamble V, Unverzagt FW, Shen J & Hendrie H: Cholesterol, APOE genotype, and Alzheimer disease: an epidemiologic study of Nigerian Yoruba. Neurology 2006; 66:223-7.
19. Hayashi T & Su TP: Sigma-1 receptor ligands: potential in the treatment of neuropsychiatric disorders. CNS Drugs 2004; 18:269-84.
20. Holland AJ, Hon J, Huppert FA & Stevens F: Incidence and course of dementia in people with Down's syndrome: findings from a population-based study. J Intellect. Disabil. Res 2000; 44:138-46.
21. Jellinger KA & Bancher C: Neuropathology of Alzheimer's disease: a critical update. J Neural Transm Suppl 1998; 54:77-95.
22. Jellinger KA: Alzheimer disease and cerebrovascular pathology: an update. J Neural Transm 2002; 109:813-36.
23. Kalaria RN & Ballard C: Overlap between pathology of Alzheimer disease and vascular dementia. Alzheimer Dis Assoc Disord 1999; 13:S115-23.
24. Kivipelto M, Helkala EL, Hanninen T, Laakso MP, Hallikainen M, Alhainen K, Soininen H, Tuomilehto J & Nissinen A: Midlife vascular risk factors and late-life mild cognitive impairment: a population-based study. Neurology 2001; 56:1683-9.
25. Kivipelto M, Helkala E-L, Laakso MP, Hanninen T, Hallikainen M, Alhainen K, Soininen H, Tuomilehto J & Nissinen A: Midlife vascular risk factors and Alzheimer's disease in later life: longitudinal, population based study. BMJ 2001; 322:1447-51.
26. Konturek PC, Burnat G & Hahn EG: Inhibition of Barret's adenocarcinoma cell growth by simvastatin: involvement of COX-2 and apoptosis-related proteins. J Physiol Pharmacol 2007; 58:141-8.
27. Ledesma MD, Abad-Rodriguez J, Galvan C, Biondi E, Navarro P, Delacourte A, Dingwall C & Dotti CG: Raft disorganization leads to reduced plasmin activity in Alzheimer's disease brains. EMBO Rep 2003; 4:1190-6.
28. Lesser G, Kandiah K, Libow LS, Likourezos A, Breuer B, Marin D, Mohs R, Haroutunian V & Neufeld R: Elevated serum total and LDL cholesterol in very old patients with Alzheimer's disease. Dement Geriatr Cogn Disord 2001; 12:138-45.
29. Mann KM, Thorngate FE, Katoh-Fukui Y, Hamanaka H, Williams DL, Fujita S & Lamb BT: Independent effects of APOE on cholesterol metabolism and brain Abeta levels in an Alzheimer disease mouse model. Hum Mol Genet 2004; 13:1959-68.
30. Martins IJ, Hone E, Foster JK, Sünram-Lea SI, Gnjec A, Fuller SJ, Nolan D, Gandy SE & Martins RN: Apolipoprotein E, cholesterol metabolism, diabetes, and the convergence of risk factors for Alzheimer's disease and cardiovascular disease. Mol Psychiatty 2006; 11:721-36.
31. Mazighi M, Lavallée PC, Labreuche J & Amarenco P: Statin therapy and stroke prevention: what was known, what is new and what is next? Curr Opin Lipidol 2007;18:622-5.
32. Menzel HJ, Kladetzky RG & Assmann G: Apolipoprotein E polymorphism and coronary artery disease. Arteriosclerosis 1983; 3: 310-5.
33. Notkola IL, Sulkava R, Pekkanen J, Erkinjuntti T, Ehnholm C, Kivinen P, Tuomilehto J & Nissinen A: Serum total cholesterol, apolipoprotein E epsilon 4 allele, and Alzheimer's disease. Neuroepidemiology 1998; 17:14-20.
34. O'Brien JT, Erkinjuntti T & Reisberg B: Vascular cognitive impairment. Lancet Neurol 2003; 2:89-98.
35. O'Regan C, Wu P, Arora P, Perri D & Mills EJ: Statin therapy in stroke prevention: a meta-analysis involving 121,000 patients. Am J Med 2008;121:24-33.
36. Parnetti L, Amici S, Lanari A, Romani C, Antognelli C, Andreasen N, Minthon L, Davidsson P, Pottel H, Blennow K & Gallai V: Cerebrospinal fluid levels of biomarkers and activity of acetylcholinesterase (AChE) and butyrylcholinesterase in AD patients before and after treatment with different AChE inhibitors. Neurol Sci 2002; 23 Suppl 2:S95-6.
37. Pedrini S, Carter TL, Prendergast G, Petanceska S, Ehrlich ME & Gandy S: Modulation of statin-activated shedding of Alzheimer APP ectodomain by ROCK. PLoS Med 2005; 2:8.
38. Pregelj P, Trinkaus M, Zupan D, Trontelj JJ & Sketelj J: The role of muscle activation pattern and calcineurin in acetylcholinesterase regulation in rat skeletal muscles. J Neurosci 2007; 27:1106-13.
39. Puglielli L, Tanzi RE & Kovacs DM: Alzheimer's disease: the cholesterol connection. Nat Neurosci 2003; 6:345-51.
40. Razay G, Vreugdenhil A & Wilcock G. The metabolic syndrome and Alzheimer disease. Arch Neurol 2007; 64:93-6.
41. Rockwood K, Wentzel C & Hachinski V: Prevalence and outcomes of vascular cognitive impairment. Neurology 2000; 54:447-51.
42. Roman GC, Sachdev P & Royall DR: Vascular cognitive disorder: a new diagnostic category updating vascular cognitive impairment and vascular dementia. J Neurol Sci 2004; 226:81-7.
43. Romas SN, Tang MX, Berglund L & Mayeux R: APOE genotype, plasma lipids, lipoproteins, and AD in community elderly. Neurology 1999; 53:517-21.
44. RV Green, SE McNagny, P Jayakumar, LA Cupples, K Benke & LA Farrer: The MIRAGE Study Group, Statin use and the risk of Alzheimer's disease: the MIRAGE study. Alzheimer's Demen 2006; 2:96-103.
45. Simons M, Keller P, De Strooper B, Beyreuther K, Dotti CG & Simons K: Cholesterol depletion inhibits the generation of beta-amyloid in hippocampal neurons. Proc Natl Acad Sci U S A 1998; 95:6460-4.
46. Skoog I, Kalaria RN & Breteler MM: Vascular factors and Alzheimer disease. Alzheimer Dis Assoc Disord 1999; 13:S106-S14.
47. Snowdon DA, Greiner LH & Mortimer JA: Brain infarction and the clinical expression of Alzheimer disease. The Nun Study. JAMA 1997; 2 77:813-17.
48. Sorrentino MJ: Implications of the metabolic syndrome: the new epidemic. Am J Cardiol 2005; 96:3E-7E.
49. Sparks DL, Connor DJ, Sabbagh MN, Petersen RB, Lopez J & Browne P: Circulating cholesterol levels, apolipoprotein E genotype and dementia severity influence the benefit of atorvastatin treatment in Alzheimer's disease: results of the Alzheimer's Disease Cholesterol-Lowering Treatment (ADCLT) trial. Acta Neurol Scand Suppl 2006; 185:3-7.
50. Sparks DL, Sabbagh M, Connor D, Soares H, Lopez J, Stankovic G, Johnson-Traver S, Ziolkowski C & Browne P: Statin therapy in Alzheimer's disease. Acta Neurol Scand Suppl 2006; 185:78-86.
51. Sparks DL, Sabbagh MN, Connor DJ, Lopez J, Launer LJ, Browne P, Wasser D, Johnson-Traver S, Lochhead J & Ziolwolski C: Atorvastatin for the treatment of mild to moderate Alzheimer disease: preliminary results. Arch Neurol 2005; 62:753-7.
52. Stengard JH, Zerba KE, Pekkanen J, Ehnholm C, Nissinen A & Sing CF: Apolipoprotein E polymorphism predicts death from coronary heart disease in a longitudinal study of elderly Finnish men. Circulation 1995; 91: 265-9.
53. Strittmatter WJ, Saunders AM, Schmechel D, Pericak-Vance M, Enghild J, Salvesen, GS & Roses AD: Apolipoprotein E: high-avidity binding to beta-amyloid and increased frequency of type 4 allele in late-onset familial Alzheimer disease. Proc Natl Acad Sci. USA 1993; 90:1977-81.
54. Trojanowski JQ & Lee VM: "Fatal attractions" of proteins. A comprehensive hypothetical mechanism underlying Alzheimer's disease and other neurodegenerative disorders. Ann N Y Acad Sci 2000; 924:62-7.
55. Vanhanen M, Koivisto K, Moilanen L, Helkala EL, Hänninen T, Soininen H, Kervinen K, Kesäniemi YA, Laakso M & Kuusisto J: Association of metabolic syndrome with Alzheimer disease: a population-based study. Neurology 2006; 67(5):843-7.
56. Weisgraber KH, Innerarity TL & Mahley RW: Abnormal lipoprotein receptor-binding activity of the human E apoprotein due to cysteine-arginine interchange at a single site. J Biol Chem 1982; 257: 2518-21.
57. Wolozin B: Cholesterol and the biology of Alzheimer's disease. Neuron 41:2004; 7-10.
58. Yaffe K, Barrett-Connor E, Lin F & Grady D: Serum lipoprotein levels, statin use, and cognitive function in older women. Arch. Neurol 2002; 59:378-84.
59. Yaffe K, Kanaya A & Lindquist K, et al: The metabolic syndrome, inflammation, and risk of cognitive decline. JAMA 2004; 292:2237-42.
60. Yatesa D, & McLoughlina DM: The molecular pathology of Alzheimer's disease. Psychiatry 2008; 1:1-5.
61. Zandi PP, Sparks DL, Khachaturian AS, Tschanz J, Norton M, Steinberg M, Welsh-Bohmer KA & Breitner JCS: The Cache County Study Investigators, Do statins reduce risk of incident dementia and Alzheimer disease?: the Cache County Study. Arch Gen Psychiatr 2005; 62:217-24.
62. Zhao WQ, De Felice FG, Fernandez S, Chen H, Lambert MP, Quon MJ, Kraff GA & Klein WL: Amyloid beta oligomers induce impairment of neuronal insulin receptors. FASEB J 2008; 22:246-60.